Brilinta Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of AstraZeneca’s ticagrelor.
You may also be interested in...
Brilinta Reviewers
FDA staff that participated in the review of AstraZeneca’s anticoagulant.
Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge
The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.
Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience
FDA’s review of AstraZeneca’s platelet inhibitor ticagrelor was tinged by the agency’s earlier evaluation and delayed approval of Lilly/Daiichi’s prasugrel for acute coronary syndromes.